October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
|Articles|August 16, 2022
Daily Medication Pearl: Febuxostat (Uloric)
Author(s)Saro Arakelians, PharmD
Febuxostat) Uloric is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.
Advertisement
Medication Pearl of the Day: Febuxostat (Uloric)
Indication: Febuxostat (Uloric) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia.
Insight:
- Dosing: Febuxostat is recommended at 40 mg or 80 mg once daily. The recommended starting dose is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg/dL after 2 weeks with 40 mg, Uloric 80 mg is recommended.
- Dosage forms: Tablet 40 mg, 80 mg.
- Adverse events: Adverse reactions occurring in at least 1% of patients treated with Febuxostat and at least 0.5% greater than placebo are liver function abnormalities, nausea, arthralgia, and rash.
- Mechanism of action: Uloric, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
2
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
5